Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 7%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics is poised for success with its differentiated pipeline of biologic therapies targeting well-established mechanisms of action, specifically in the inflammatory and immunology markets. The recent acquisition by AbbVie brings validation to the company's potential and helps to mitigate risks. The company's longer-acting dosing and potential for deeper and broader clinical benefits, along with potential catalysts in the near future, make for an exciting investment opportunity.

Bears say

Apogee Therapeutics is facing numerous challenges in commercializing their lead program zumilokibart, including potential safety issues and ABBV's decision to not include APG-279 in their sales estimates. This has led to a revision of the company's fair value estimate to $135/shr, a decrease from previous estimates. Additionally, the company faces challenges in terms of diverse hiring and sustainable practices, which could potentially impact their future growth and success.

APGE has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 7% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Buy based on their latest research and market trends.

According to 15 analysts, APGE has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.